Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: Eyepoint - The Real Truth

EYPT Stock Layoffs: What to Know About the Latest EyePoint Job Cuts

EyePoint stock plummets on another trial disappointment and subsequent layoff announcement. Jefferies cuts price target for EYPT shares.

Barchart · Oct 19

Eye Insert Missed Its Main Vision Goal in a Late Stage Trial but Cut Injections Sharply

EyePoint's DURAVYU missed its primary vision endpoint in the LUGANO trial for wet AMD, despite reducing injection burden by 42 percent.

Medical Daily · Aug 20

EyePoint's drug for age-related eye disease fails late-stage trial, shares tank 70%

EyePoint's experimental drug Duravyu failed a late-stage trial for a serious eye disease. The company's shares dropped significantly after the disappointing trial results were announced. This failure impacts EyePoint's goal to compete with Regeneron's successful Eylea treatment. Analysts suggest investors will await further study confirmation for the drug's viability. EyePoint…

The Economic Times · Aug 17

From analysis to the latest developments in health,
read the most diverse news in one place.

EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears

Eyepoint Pharmaceuticals (NASDAQ:EYPT) executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as EYP-1901, beginning in August, with a second pivotal trial expected to follow about two months later.

MarketBeat · May 26

The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside

These biotech bets are only for investors who can stomach volatility.

Barchart · Dec 20, 2025

EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shared details on Tuesday about its pivotal Phase 3 program of Duravyu (vorolanib intravitreal insert) for diabetic macular edema (DME) and began first patient dosing, anticipated in the first quarter of 2026.

Benzinga · Oct 15, 2025

Breakout Momentum Plays You May Not Know About

Momentum investing is all about timing—these three under-the-radar stocks have begun to rise by still seem to have room for further growth.

MarketBeat · Jun 6, 2025

Read news from The Economist, FT, and more,
with one subscription

2 Small-Cap Stocks Under $20 With Over 220% Upside Potential

Wall Street is forecasting multibagger returns from these two small-cap biotech stocks over the next year.

Barchart · Aug 4, 2024

EyePoint, Expands Pact With Betta Pharma For EYP-1901 In China, Posts Deeper Q1 Loss

EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) executed a license agreement with Betta Pharmaceuticals Co Ltd to develop and commercialize EYP-1901 in Mainland China, Hong Kong, Macau, and Taiwan. This agreement expands the collaboration between EyePoint and Equinox Sciences, LLC, a Betta Pharmaceuticals affiliate established in February 2020. EyePoint will retain global ophthalmic rights for EYP-1901 in the…

Benzinga · May 4, 2022

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.